Development of a 3-day manufacturing method to generate CD19-CD20-CD22 trispecific CAR T-cells from whole blood.
CAR T-cell manufacturing can now happen in 3 days instead of 7 while maintaining quality, potentially making life-saving cancer therapy faster.
A 3-day GMP-compliant whole-blood trispecific (CD19/CD20/CD22) CAR T-cell manufacturing process produces products with >95% viability, 53% transduction efficiency, stem-like phenotype, and cytotoxicity equivalent to standard 7-day products. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- translational manufacturing and functional characterization
- Category
- novel_therapeutics
- Maturity
- Validated
- Journal
- J Transl Med
Why it surfaced
NIH-developed novel 3-day trispecific CAR-T manufacturing approach from whole blood addressing key barriers (time, cost, accessibility) in B-cell malignancy treatment, with favorable phenotypic profile.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.